Johnson & Johnson

NYSE:JNJ

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

💄 Cosmetics

💊 Drugstores & Retail Pharmacies

🧴 Personal Care

🛍 Specialty Retail

Location

United States

Market Cap

USD 366.71 B

Share Price

USD 152.41

Avg Daily Volume

9,317,871

Change (1 day)

0.26%

Change (1 year)

4.53%

Change (YTD)

5.39%

Johnson & Johnson Research and Development (R&D) Expenses for the Trailing 12 Months (TTM) ending March 30, 2025: USD 16.91 B

Johnson & Johnson Research and Development (R&D) Expenses is USD 16.91 B for the Trailing 12 Months (TTM) ending March 30, 2025, a 11.49% change year over year. Research and development (R&D) expenses are the costs associated with the development of new products, technologies, or improvements to existing products.

Johnson & Johnson Research and Development (R&D) Expenses for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 15.17 B, a -0.62% change year over year.
Johnson & Johnson Research and Development (R&D) Expenses for the Trailing 12 Months (TTM) ending April 02, 2023 was USD 15.27 B, a -2.18% change year over year.
Johnson & Johnson Research and Development (R&D) Expenses for the Trailing 12 Months (TTM) ending April 03, 2022 was USD 15.61 B, a 22.35% change year over year.
Johnson & Johnson Research and Development (R&D) Expenses for the Trailing 12 Months (TTM) ending April 04, 2021 was USD 12.76 B, a 15.17% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Research and Development (R&D) Expenses	Revenue	Revenue	Gross Profit

NYSE: JNJ

Johnson & Johnson

CEO	Mr. Joaquin Duato
IPO Date	Jan. 2, 1943
Location	United States
Headquarters	One Johnson & Johnson Plaza
Employees	138,100
Sector	🏥 Health Care
Industries Pharmaceuticals 💄 Cosmetics 💊 Drugstores & Retail Pharmacies 🧴 Personal Care 🛍 Specialty Retail

Description

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.